Dawnrays Pharmaceutical Holdings Ltd. Annual Results: Standalone & Consolidated Reports

Annual Results

Results Snapshot

Figures in Million

Consolidate Annual Results

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Dec'18

Net Sales

1,149.61

1,272.01

1,485.79

1,404.26

1,150.97

1,077.23

1,123.97

Other Operating Income

0.00

Total Operating income

1,149.61

1,272.01

1,485.79

1,404.26

1,150.97

1,077.23

1,123.97

Raw Material Cost

552.33

594.45

613.83

605.99

552.12

487.24

432.22

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

241.38

227.04

210.51

195.67

163.44

148.41

150.31

Power Cost

0.00

Manufacturing Expenses

3.91

1.09

0.43

0.77

5.43

6.02

1.36

Selling and Distribution Expenses

248.74

263.82

288.60

254.20

166.94

136.31

157.93

Other Expenses

-16.86

-13.46

-12.40

-11.98

-10.65

-10.01

-9.73

Total Expenditure (Excl Depreciation)

877.79

951.77

989.42

936.88

781.38

677.85

644.56

Operating Profit (PBDIT) excl Other Income

271.8

320.20000000000005

496.4

467.40000000000003

369.6

399.4

479.4

Other Income

469.36

36.90

85.07

119.23

24.08

-19.09

-8.48

Operating Profit (PBDIT)

807.24

435.72

651.07

648.85

454.90

443.14

533.80

Interest

3.91

1.09

0.43

0.77

5.43

6.02

1.36

Exceptional Items

6.74

160.79

8.39

6.70

10.85

-4.70

-7.18

Gross Profit (PBDT)

597.28

677.56

871.95

798.26

598.85

589.99

691.75

Depreciation

115.46

92.65

77.23

69.35

66.95

62.85

61.15

Profit Before Tax

694.60

502.76

581.80

585.42

393.37

369.57

464.10

Tax

80.44

100.99

96.00

102.64

74.73

66.60

87.43

Provisions and contingencies

0.00

Profit After Tax

612.52

360.23

416.38

431.68

301.30

289.64

360.03

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

612.52

360.23

416.38

431.68

301.30

289.64

360.03

Share in Profit of Associates

0.00

Minority Interest

-2.36

-3.68

-2.57

-4.84

-3.75

-0.08

0.00

Other related items

0.00

Consolidated Net Profit

610.16

356.55

413.81

426.84

297.55

289.55

360.03

Equity Capital

0.00

Face Value

0.0

0.06

Reserves

3,537.73

3,142.99

2,966.23

2,912.25

2,573.44

2,265.87

2,190.81

Earnings per share (EPS)

0.41

0.24

0.28

0.29

0.19

0.18

0.23

Diluted Earnings per share

0.41

0.24

0.28

0.29

0.19

0.18

0.23

Operating Profit Margin (Excl OI)

19.35%

24.07%

32.9%

32.78%

31.61%

37.07%

42.81%

Gross Profit Margin

70.46%

46.81%

44.36%

46.63%

39.99%

40.14%

46.73%

PAT Margin

53.28%

28.32%

28.02%

30.74%

26.18%

26.89%

32.03%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Annual Analysis Highlights

Net Sales

YoY Growth in year ended Dec 2024 is -9.62% vs -14.39% in Dec 2023

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 71.16% vs -13.85% in Dec 2023

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is -15.27% vs -29.54% in Dec 2023

Interest

YoY Growth in year ended Dec 2024 is 254.55% vs 175.00% in Dec 2023

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has fallen from Dec 2023

Compare Annual Results Of Dawnrays Pharmaceutical Holdings Ltd. With

Select Peers

Figures in Million

Consolidate Annual Results

Change(HKD)

Change(%)

Net Sales

1,149.61

6,206.58

-5,056.97

-81.48%

Other Operating Income

0.00

Total Operating income

1,149.61

6,206.58

-5,056.97

-81.48%

Raw Material Cost

552.33

1,731.39

-1,179.06

-68.10%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

241.38

1,795.66

-1,554.28

-86.56%

Power Cost

0.00

Manufacturing Expenses

3.91

133.24

-129.33

-97.07%

Selling and Distribution Expenses

248.74

2,475.80

-2,227.06

-89.95%

Other Expenses

-16.86

-86.85

69.99

80.59%

Total Expenditure (Excl Depreciation)

877.79

5,267.59

-4,389.80

-83.34%

Operating Profit (PBDIT) excl Other Income

271.82

939.00

-667.18

-71.05%

Other Income

469.36

111.36

358.00

321.48%

Operating Profit (PBDIT)

807.24

1,456.73

-649.49

-44.59%

Interest

3.91

133.24

-129.33

-97.07%

Exceptional Items

6.74

0.00

6.74

Gross Profit (PBDT)

597.28

4,475.19

-3,877.91

-86.65%

Depreciation

115.46

406.37

-290.91

-71.59%

Profit Before Tax

694.60

917.12

-222.52

-24.26%

Tax

80.44

27.55

52.89

191.98%

Provisions and contingencies

0.00

Profit After Tax

612.52

889.57

-277.05

-31.14%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

612.52

889.57

-277.05

-31.14%

Share in Profit of Associates

0.00

Minority Interest

-2.36

0.00

-2.36

Other related items

0.00

Consolidated Net Profit

610.16

889.57

-279.41

-31.41%

Equity Capital

0.00

Face Value

0.00

1.06

0.00

Reserves

3,537.73

3,207.13

330.60

10.31%

Earnings per share (EPS)

0.41

1.64

-1.23

-75.00%

Diluted Earnings per share

0.41

1.64

-1.23

-75.00%

Operating Profit Margin (Excl OI)

19.35%

15.13%

0.00

4.22%

Gross Profit Margin

70.46%

21.32%

0.00

49.14%

PAT Margin

53.28%

14.33%

0.00

38.95%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Annual - Net Sales

Net Sales 114.96 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is -9.62% vs -14.39% in Dec 2023

Annual - Consolidate Net Profit

Consolidate Net Profit 61.02 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is 71.16% vs -13.85% in Dec 2023

Annual - Operating Profit (PBDIT)

Operating Profit (PBDIT) 33.79 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is -15.27% vs -29.54% in Dec 2023

Annual - Interest

Interest 0.39 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is 254.55% vs 175.00% in Dec 2023

Annual - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 19.35%

in Dec 2024

Figures in %

YoY Growth in year ended Dec 2024 has fallen from Dec 2023